Clinical Trial Update: NB-001 Treatment of Recurrent Herpes Labialis [Phase 3]

View source ↗

Summary

Phase 3 clinical trial update for NB-001 in recurrent herpes labialis is underway. The sponsor is NanoBio Corporation, but the current status is not disclosed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Herpes Labialis

Drugs mentioned

• NB-001

Snippet

Sponsor: NanoBio Corporation | Conditions: Herpes Labialis | Phase 3 | Status: UNKNOWN